Kashiv BioSciences Enters Into Exclusive Licensing Agreement With Amneal For Commercialization Of A Proposed Biosimilar To XOLAIR
Portfolio Pulse from Benzinga Newsdesk
Kashiv BioSciences has entered into an exclusive licensing agreement with Amneal Pharmaceuticals for the commercialization of ADL018, a proposed biosimilar to XOLAIR. This builds on their successful U.S. biosimilar partnership for two oncology products. ADL018 is currently in Phase III clinical trials.
July 01, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amneal Pharmaceuticals has entered into an exclusive licensing agreement with Kashiv BioSciences to commercialize ADL018, a proposed biosimilar to XOLAIR. This partnership builds on their previous successful collaborations in the U.S. biosimilar market.
The exclusive licensing agreement for ADL018, a proposed biosimilar to XOLAIR, is likely to positively impact Amneal Pharmaceuticals. This partnership builds on their previous successful collaborations, indicating strong potential for market success.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100